Chronic Wounds Research

What is a chronic wound?

A chronic wound is a wound that does not heal in an orderly set of stages in a predictable amount of time. Wounds that do not heal within three months are often considered chronic. Chronic wounds seem to be detained in one or more of the traditional phases of wound healing. To overcome a stall in healing, a number of factors need to be addressed such as necrotic tissue, moisture balance, and particularly bioburden. Chronic wounds cause patients severe emotional and physical stress and create a significant financial burden on patients and the healthcare system.

Causes of Chronic Wounds

In addition to poor circulation, neuropathy, and difficulty moving, factors that contribute to chronic wounds include systemic illnesses, age, and repeated trauma. Comorbid ailments that may contribute to the formation of chronic wounds include vasculitis (an inflammation of blood vessels), immune suppression, and diseases that cause ischemia, or restrictions in blood supply to tissues.

Chronic wounds may affect only the epidermis and dermis, or they may affect tissues all the way to the fascia. They may be formed originally by the same things that cause acute ones, such as surgery or accidental trauma, or they may form as the result of systemic infection, vascular, immune or nerve insufficiency, or comorbidities such as neoplasias or metabolic disorders.

The reason a wound becomes chronic is that the body’s ability to deal with the damage is overwhelmed by factors such as repeated trauma, excessive bioburden, continued pressure, ischemia, or illness.


Our Impact

Turn Therapeutics® made its technology debut in chronic/advanced wound care. Our first commercially available product, Hexagen® Antimicrobial Wound Dressing, showcased the simultaneous potency and gentleness of the PermaFusion® delivery system when combined with known and trusted biologically active ingredients.

Hexagen® quickly became the chronic wound product of choice by clinicians nationwide at prestigious treatment centers. Prestigious academic centers have shown Hexagen® to significantly reduce healing times with less side effects than previous standard of care tools.

Turn Therapeutics® is conducting research and development in chronic and advanced wounds on an ongoing basis. Our platform delivery technology, PermaFusion®, will enable effective delivery of additional biologically active ingredients, such as biologic cell lines.


Our work—aimed at discovering cures—is a constant evolution and a challenge to the status quo. If modern medicine is the book, we will be the next breakthrough chapter.

– Bradley Burnam, CEO

Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX